Ahmed Alsaati, Turki Hakami, Sultan Bajawi, Gamil Mohammed, Nouf Bajawi, Nadya Al-Faraidy
{"title":"慢性髓系白血病中一种罕见的血管表现：尼洛替尼治疗期间Bier斑的1例报告及文献复习。","authors":"Ahmed Alsaati, Turki Hakami, Sultan Bajawi, Gamil Mohammed, Nouf Bajawi, Nadya Al-Faraidy","doi":"10.4081/dr.2025.10160","DOIUrl":null,"url":null,"abstract":"<p><p>Bier's spots are rare angiospastic macules often associated with physiologic vasoconstriction. This case report describes a 35-year-old man with chronic myeloid leukemia (CML) treated with nilotinib who developed Bier's spots, a previously unreported adverse effect of the drug. The patient presented with asymptomatic hypopigmented macules on the hands and legs that appeared during venous stasis and resolved with elevation. This case emphasizes the need to recognize potential vascular side effects of tyrosine kinase inhibitors (TKIs) and highlights Bier's spots as a benign but remarkable manifestation in patients undergoing nilotinib therapy.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12522193/pdf/","citationCount":"0","resultStr":"{\"title\":\"A rare vascular manifestation in chronic myeloid leukemia: a case report and literature review of Bier's spot development during nilotinib treatment.\",\"authors\":\"Ahmed Alsaati, Turki Hakami, Sultan Bajawi, Gamil Mohammed, Nouf Bajawi, Nadya Al-Faraidy\",\"doi\":\"10.4081/dr.2025.10160\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Bier's spots are rare angiospastic macules often associated with physiologic vasoconstriction. This case report describes a 35-year-old man with chronic myeloid leukemia (CML) treated with nilotinib who developed Bier's spots, a previously unreported adverse effect of the drug. The patient presented with asymptomatic hypopigmented macules on the hands and legs that appeared during venous stasis and resolved with elevation. This case emphasizes the need to recognize potential vascular side effects of tyrosine kinase inhibitors (TKIs) and highlights Bier's spots as a benign but remarkable manifestation in patients undergoing nilotinib therapy.</p>\",\"PeriodicalId\":11049,\"journal\":{\"name\":\"Dermatology Reports\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12522193/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/dr.2025.10160\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/31 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/dr.2025.10160","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
A rare vascular manifestation in chronic myeloid leukemia: a case report and literature review of Bier's spot development during nilotinib treatment.
Bier's spots are rare angiospastic macules often associated with physiologic vasoconstriction. This case report describes a 35-year-old man with chronic myeloid leukemia (CML) treated with nilotinib who developed Bier's spots, a previously unreported adverse effect of the drug. The patient presented with asymptomatic hypopigmented macules on the hands and legs that appeared during venous stasis and resolved with elevation. This case emphasizes the need to recognize potential vascular side effects of tyrosine kinase inhibitors (TKIs) and highlights Bier's spots as a benign but remarkable manifestation in patients undergoing nilotinib therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
